Dr. Mohammad A. Khalil, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 128
Licensed in Texas since 1999, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license K7566 (first issued 1999; active) -
Critical Care Medicine (Internal Medicine) Physician
WI license 51306-020 -
Pulmonary Disease Physician
WI license 51306-020 -
Sleep Medicine (Internal Medicine) Physician
WI license 51306-020
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Texoma Medical Center Denison, TX
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 128
- Services billed
- 2,178
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 495 | 127 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 348 | 50 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 320 | 49 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 61 | 59 |
| Test to examine how well the lungs exchange gases | 60 | 58 |
| Test to determine lung volumes using sensors | 56 | 54 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 43 | 38 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 28 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 19 | 19 |
| Insertion of needle into vein for collection of blood sample | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Sherman, TX | 255 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Sherman, TX | 121 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Sherman, TX | 71 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Sherman, TX | 50 |
| Pantoprazole Sodium Other prescribers in Sherman, TX | 45 |
| Fluticasone Propionate Other prescribers in Sherman, TX | 42 |
| Methylprednisolone Other prescribers in Sherman, TX | 33 |
| Losartan Potassium Other prescribers in Sherman, TX | 28 |
| Combivent Respimat (ipratropium/albuterol sulfate) Other prescribers in Sherman, TX | 27 |
| Potassium Chloride Other prescribers in Sherman, TX | 27 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 13 payments worth $262 in total to this clinician.
| GlaxoSmithKline, LLC. | $76.85 |
|---|---|
| Electromed, Inc. | $32.62 |
| Boston Scientific Corporation | $32.39 |
| Regeneron Healthcare Solutions, Inc. | $30.48 |
| AstraZeneca Pharmaceuticals LP | $22.52 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.24 |
| Novo Nordisk Inc | $17.32 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $14.64 |
| Food and Beverage | $262 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $9,957 in research payments for these studies, mostly to the institutions running them.
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.